- Home
- AUTL vs DIAX Comparison
AUTL vs DIAX Comparison
Compare AUTL & DIAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUTL
- DIAX
- Stock Information
- Founded
- AUTL 2014
- DIAX 2005
- Country
- AUTL United Kingdom
- DIAX United States
- Employees
- AUTL N/A
- DIAX N/A
- Industry
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- DIAX Finance Companies
- Sector
- AUTL Health Care
- DIAX Finance
- Exchange
- AUTL Nasdaq
- DIAX Nasdaq
- Market Cap
- AUTL 625.4M
- DIAX 537.5M
- IPO Year
- AUTL 2018
- DIAX N/A
- Fundamental
- Price
- AUTL $1.36
- DIAX $14.48
- Analyst Decision
- AUTL Strong Buy
- DIAX
- Analyst Count
- AUTL 5
- DIAX 0
- Target Price
- AUTL $9.12
- DIAX N/A
- AVG Volume (30 Days)
- AUTL 4.5M
- DIAX 96.6K
- Earning Date
- AUTL 11-11-2025
- DIAX 01-01-0001
- Dividend Yield
- AUTL N/A
- DIAX 7.93%
- EPS Growth
- AUTL N/A
- DIAX N/A
- EPS
- AUTL N/A
- DIAX N/A
- Revenue
- AUTL $29,934,000.00
- DIAX N/A
- Revenue This Year
- AUTL $641.63
- DIAX N/A
- Revenue Next Year
- AUTL $109.21
- DIAX N/A
- P/E Ratio
- AUTL N/A
- DIAX N/A
- Revenue Growth
- AUTL 185.17
- DIAX N/A
- 52 Week Low
- AUTL $1.11
- DIAX $12.80
- 52 Week High
- AUTL $5.00
- DIAX $15.12
- Technical
- Relative Strength Index (RSI)
- AUTL 33.35
- DIAX 44.99
- Support Level
- AUTL $1.26
- DIAX $14.64
- Resistance Level
- AUTL $1.46
- DIAX $14.82
- Average True Range (ATR)
- AUTL 0.09
- DIAX 0.11
- MACD
- AUTL 0.01
- DIAX -0.05
- Stochastic Oscillator
- AUTL 30.49
- DIAX 24.44
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
About DIAX Nuveen Dow 30SM Dynamic Overwrite Fund of Beneficial Interest
Nuveen Dow 30sm Dynamic Overwrite Fund is a non-diversified closed-end management investment company. Its investment objective is to seek attractive total return with less volatility than the Dow Jones Industrial Average by investing in an equity portfolio that seeks to substantially replicate the price movements of the DJIA, as well as selling call options on 35%-75% of the notional value of the Fund's equity portfolio.